Margareta Hammarlund-Udenaes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Margareta Hammarlund-Udenaes has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Irena Loryan
Department of Pharmacy, Uppsala University, Uppsala, Sweden
6 shared publications - Stina Syvänen
Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
5 shared publications - Elizabeth Cunera Maria de Lange
Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research Leiden University Leiden The Netherlands
4 shared publications - David E. Smith
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA
3 shared publications Emma Boström
3 shared publications- Sofia Gustafsson
Department of Pharmaceutical Biosciences, Translational PKPD, Box 591, 751 24, Uppsala, Sweden
3 shared publications
Latest Publications
- Open Access
- 13 February 2025
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 22 (3) , 421-439
Assessing central nervous system drug delivery
Delivering drugs to the central nervous system (CNS) remains a major challenge due to the blood-brain barrier, restricting the entry of drugs into the brain. This limitation contributes to the ongoing lack of effective treatments for CNS diseases. To improve the process of drug discovery and development, it is crucial to streamline methods that measure clinically relevant parameters, allowing for good selection of drug candidates. In this paper, we discuss the essential prerequisites for successful CNS drug delivery and review relevant methods. We emphasize the need for closer collaboration between in vitro and in vivo scientists to improve the relevance of these methods and increase the success rate of developing effective CNS therapies. While our focus is on small molecule drugs, we also touch on some aspects of larger molecules. Significant progress has been made in recent years in method development and their application. However, there is still work to be done before the use of in silico models, in vitro cell systems, and AI can consistently offer meaningful correlations and relationships to clinical data. This gap is partly due to limited patient data, but a lot can be achieved through in vivo research in animal models.
- 13 February 2025
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 22 (3) , 421-439
Open AccessAssessing central nervous system drug delivery
Delivering drugs to the central nervous system (CNS) remains a major challenge due to the blood-brain barrier, restricting the entry of drugs into the brain. This limitation contributes to the ongoing lack of effective treatments for CNS diseases. To improve the process of drug discovery and development, it is crucial to streamline methods that measure clinically relevant parameters, allowing for good selection of drug candidates. In this paper, we discuss the essential prerequisites for successful CNS drug delivery and review relevant methods. We emphasize the need for closer collaboration between in vitro and in vivo scientists to improve the relevance of these methods and increase the success rate of developing effective CNS therapies. While our focus is on small molecule drugs, we also touch on some aspects of larger molecules. Significant progress has been made in recent years in method development and their application. However, there is still work to be done before the use of in silico models, in vitro cell systems, and AI can consistently offer meaningful correlations and relationships to clinical data. This gap is partly due to limited patient data, but a lot can be achieved through in vivo research in animal models.
- Open Access
- 1 November 2019
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 14, 2451-2460
A Cross-Sectional Study Assessing Appropriateness Of Inhaled Corticosteroid Treatment In Primary And Secondary Care Patients With COPD In Sweden
Purpose: Inhaled corticosteroids (ICS) are often more widely prescribed in the treatment of chronic obstructive pulmonary disease (COPD) than what is recommended in the guidelines. The aim of this study was to evaluate the appropriateness of ICS treatment in COPD patients using the algorithm proposed by the International Primary Care Respiratory Group (IPCRG) and to identify factors associated with ICS treatment. Patients and methods: Appropriateness of ICS therapy was studied with respect to concomitant asthma, history of exacerbations and blood eosinophils (B-Eos) in a Swedish cohort of primary and secondary care patients with COPD. Factors associated with ICS were investigated using multivariable logistic regression. Results: Triple treatment was found to be the most common treatment combination, used by 46% of the 561 included patients, and in total 63% were using ICS. When applying the IPCRG algorithm, there was a possible indication for discontinuation of ICS in 55% of the patients with ICS treatment. Of the patients not using ICS, 18% had an indication for starting such treatment. The strongest factors associated with ICS therapy were frequent exacerbations (aOR 8.61, 95% CI 4.06, 20.67), secondary care contacts (aOR 6.99, 95% CI 2.48, 25.28) and very severe airflow limitation (aOR 5.91, 95% CI 1.53, 26.58). Conclusion: More than half of the COPD patients on ICS met the criteria where withdrawal of the treatment could be tried. There was, however, also a subgroup of patients not using ICS for whom there was an indication for starting ICS treatment. Patients using ICS were characterized by more frequent exacerbations and lower lung function.
- 1 November 2019
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 14, 2451-2460
Open AccessA Cross-Sectional Study Assessing Appropriateness Of Inhaled Corticosteroid Treatment In Primary And Secondary Care Patients With COPD In Sweden
Purpose: Inhaled corticosteroids (ICS) are often more widely prescribed in the treatment of chronic obstructive pulmonary disease (COPD) than what is recommended in the guidelines. The aim of this study was to evaluate the appropriateness of ICS treatment in COPD patients using the algorithm proposed by the International Primary Care Respiratory Group (IPCRG) and to identify factors associated with ICS treatment. Patients and methods: Appropriateness of ICS therapy was studied with respect to concomitant asthma, history of exacerbations and blood eosinophils (B-Eos) in a Swedish cohort of primary and secondary care patients with COPD. Factors associated with ICS were investigated using multivariable logistic regression. Results: Triple treatment was found to be the most common treatment combination, used by 46% of the 561 included patients, and in total 63% were using ICS. When applying the IPCRG algorithm, there was a possible indication for discontinuation of ICS in 55% of the patients with ICS treatment. Of the patients not using ICS, 18% had an indication for starting such treatment. The strongest factors associated with ICS therapy were frequent exacerbations (aOR 8.61, 95% CI 4.06, 20.67), secondary care contacts (aOR 6.99, 95% CI 2.48, 25.28) and very severe airflow limitation (aOR 5.91, 95% CI 1.53, 26.58). Conclusion: More than half of the COPD patients on ICS met the criteria where withdrawal of the treatment could be tried. There was, however, also a subgroup of patients not using ICS for whom there was an indication for starting ICS treatment. Patients using ICS were characterized by more frequent exacerbations and lower lung function.
- 1 October 2019
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (10) , 3425-3433
Understanding the Influence of Nanocarrier-Mediated Brain Delivery on Therapeutic Performance Through Pharmacokinetic-Pharmacodynamic Modeling
- 1 October 2019
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (10) , 3425-3433
Understanding the Influence of Nanocarrier-Mediated Brain Delivery on Therapeutic Performance Through Pharmacokinetic-Pharmacodynamic Modeling
- 1 June 2019
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 139, 197-204
Targeted brain delivery of methotrexate by glutathione PEGylated liposomes: How can the formulation make a difference?
- 1 June 2019
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 139, 197-204
Targeted brain delivery of methotrexate by glutathione PEGylated liposomes: How can the formulation make a difference?
- Open Access
- 1 December 2018
- Published by Elsevier in Neuropharmacology
- Vol. 143, 1-9
Blood-brain barrier integrity in a mouse model of Alzheimer's disease with or without acute 3D6 immunotherapy
- 1 December 2018
- Published by Elsevier in Neuropharmacology
- Vol. 143, 1-9
Open AccessBlood-brain barrier integrity in a mouse model of Alzheimer's disease with or without acute 3D6 immunotherapy
- 1 November 2018
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 124, 182-187
Rate of small-molecular drug transport across the blood-brain barrier in a pericyte-deficient state
- 1 November 2018
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 124, 182-187
Rate of small-molecular drug transport across the blood-brain barrier in a pericyte-deficient state
- 1 September 2018
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 122, 77-84
Pharmacokinetics of pericyte involvement in small-molecular drug transport across the blood-brain barrier
- 1 September 2018
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 122, 77-84
Pharmacokinetics of pericyte involvement in small-molecular drug transport across the blood-brain barrier
- Open Access
- 1 January 2018
- Published by Elsevier in Neuropharmacology
- Vol. 128, 482-491
Intact blood-brain barrier transport of small molecular drugs in animal models of amyloid beta and alpha-synuclein pathology
- 1 January 2018
- Published by Elsevier in Neuropharmacology
- Vol. 128, 482-491
Open AccessIntact blood-brain barrier transport of small molecular drugs in animal models of amyloid beta and alpha-synuclein pathology
- Open Access
- 7 November 2017
- Published by Springer Nature in Fluids and Barriers of the CNS
- Vol. 14 (1) , 31
Current research into brain barriers and the delivery of therapeutics for neurological diseases: a report on CNS barrier congress London, UK, 2017
This is a report on the CNS barrier congress held in London, UK, March 22–23rd 2017 and sponsored by Kisaco Research Ltd. The two 1-day sessions were chaired by John Greenwood and Margareta Hammarlund-Udenaes, respectively, and each session ended with a discussion led by the chair. Speakers consisted of invited academic researchers studying the brain barriers in relation to neurological diseases and industry researchers studying new methods to deliver therapeutics to treat neurological diseases. We include here brief reports from the speakers.
- 7 November 2017
- Published by Springer Nature in Fluids and Barriers of the CNS
- Vol. 14 (1) , 31
Open AccessCurrent research into brain barriers and the delivery of therapeutics for neurological diseases: a report on CNS barrier congress London, UK, 2017
This is a report on the CNS barrier congress held in London, UK, March 22–23rd 2017 and sponsored by Kisaco Research Ltd. The two 1-day sessions were chaired by John Greenwood and Margareta Hammarlund-Udenaes, respectively, and each session ended with a discussion led by the chair. Speakers consisted of invited academic researchers studying the brain barriers in relation to neurological diseases and industry researchers studying new methods to deliver therapeutics to treat neurological diseases. We include here brief reports from the speakers.
- Open Access
- 31 October 2017
- Published by Springer Nature in Fluids and Barriers of the CNS
- Vol. 14 (1) , 30
Revisiting atenolol as a low passive permeability marker
Atenolol, a hydrophilic beta blocker, has been used as a model drug for studying passive permeability of biological membranes such as the blood–brain barrier (BBB) and the intestinal epithelium. However, the extent of S-atenolol (the active enantiomer) distribution in brain has never been evaluated, at equilibrium, to confirm that no transporters are involved in its transport at the BBB. To assess whether S-atenolol, in fact, depicts the characteristics of a low passive permeable drug at the BBB, a microdialysis study was performed in rats to monitor the unbound concentrations of S-atenolol in brain extracellular fluid (ECF) and plasma during and after intravenous infusion. A pharmacokinetic model was developed, based on the microdialysis data, to estimate the permeability clearance of S-atenolol into and out of brain. In addition, the nonspecific binding of S-atenolol in brain homogenate was evaluated using equilibrium dialysis. The steady-state ratio of unbound S-atenolol concentrations in brain ECF to that in plasma (i.e., Kp,uu,brain) was 3.5% ± 0.4%, a value much less than unity. The unbound volume of distribution in brain (Vu, brain) of S-atenolol was also calculated as 0.69 ± 0.10 mL/g brain, indicating that S-atenolol is evenly distributed within brain parenchyma. Lastly, equilibrium dialysis showed limited nonspecific binding of S-atenolol in brain homogenate with an unbound fraction (fu,brain) of 0.88 ± 0.07. It is concluded, based on Kp,uu,brain being much smaller than unity, that S-atenolol is actively effluxed at the BBB, indicating the need to re-consider S-atenolol as a model drug for passive permeability studies of BBB transport or intestinal absorption.
- 31 October 2017
- Published by Springer Nature in Fluids and Barriers of the CNS
- Vol. 14 (1) , 30
Open AccessRevisiting atenolol as a low passive permeability marker
Atenolol, a hydrophilic beta blocker, has been used as a model drug for studying passive permeability of biological membranes such as the blood–brain barrier (BBB) and the intestinal epithelium. However, the extent of S-atenolol (the active enantiomer) distribution in brain has never been evaluated, at equilibrium, to confirm that no transporters are involved in its transport at the BBB. To assess whether S-atenolol, in fact, depicts the characteristics of a low passive permeable drug at the BBB, a microdialysis study was performed in rats to monitor the unbound concentrations of S-atenolol in brain extracellular fluid (ECF) and plasma during and after intravenous infusion. A pharmacokinetic model was developed, based on the microdialysis data, to estimate the permeability clearance of S-atenolol into and out of brain. In addition, the nonspecific binding of S-atenolol in brain homogenate was evaluated using equilibrium dialysis. The steady-state ratio of unbound S-atenolol concentrations in brain ECF to that in plasma (i.e., Kp,uu,brain) was 3.5% ± 0.4%, a value much less than unity. The unbound volume of distribution in brain (Vu, brain) of S-atenolol was also calculated as 0.69 ± 0.10 mL/g brain, indicating that S-atenolol is evenly distributed within brain parenchyma. Lastly, equilibrium dialysis showed limited nonspecific binding of S-atenolol in brain homogenate with an unbound fraction (fu,brain) of 0.88 ± 0.07. It is concluded, based on Kp,uu,brain being much smaller than unity, that S-atenolol is actively effluxed at the BBB, indicating the need to re-consider S-atenolol as a model drug for passive permeability studies of BBB transport or intestinal absorption.